Research programme: small molecule therapeutics - Exelixis/GlaxoSmithKline
Latest Information Update: 24 Jan 2008
At a glance
- Originator Exelixis
- Developer Exelixis; GlaxoSmithKline
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation; Vascular disorders
Most Recent Events
- 28 Oct 2002 Preclinical trials in Cancer in USA (unspecified route)
- 28 Oct 2002 Preclinical trials in Inflammation in USA (unspecified route)
- 28 Oct 2002 Preclinical trials in Vascular disorders in USA (unspecified route)